← Back to home

Bladder (urothelial, transitional cell) cancer superficial (non-invasive)

Clinical trials for Bladder (urothelial, transitional cell) cancer superficial (non-invasive) explained in plain language.

Never miss a new study

Get alerted when new Bladder (urothelial, transitional cell) cancer superficial (non-invasive) trials appear

Sign up with your email to follow new studies for Bladder (urothelial, transitional cell) cancer superficial (non-invasive), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

New bladder cancer drug could spare patients from bladder removal

Disease control Not yet recruiting

This Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…

Matched conditions: BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER SUPERFICIAL (NON-INVASIVE)

Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control

Last updated Sep 04, 2026 00:00 UTC

Bladder (urothelial, transitional cell) cancer superficial (non-invasive)

Get alerted when new Bladder (urothelial, transitional cell) cancer superficial (non-invasive) trials appear

New bladder cancer drug could spare patients from bladder removal